Ask AI

Navigating HER2-Negative MBC: An Oncology Nurse Roadmap to Maximize Efficacy and Enhance Tolerability With Antibody–Drug Conjugates

Learn more about the antibody–drug conjugate landscape for patients with HER2-negative metastatic breast cancer and optimal measures to recognize the associated adverse events and implement early intervention strategies to preserve quality of life for patients through an on-demand webcast with accompanying downloadable slides, expert-authored commentary, and a downloadable resource pocket guide.

Share

Program Content

Events

Activities

ADCs for HER2 Negative MBC
Navigating HER2-Negative MBC: An Oncology Nurse Roadmap to Maximize Efficacy and Enhance Tolerability With Antibody–Drug Conjugates
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 02, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

Supporters

This activity is supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.